Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stem cell issue reemerges

The coincidence of the selection of a new director of the National Institutes of Health and NIH efforts to finalize its draft Guidelines for Research Involving Human Pluripotent Stem Cells could complicate both issues.

Read the full 343 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE